Details for New Drug Application (NDA): 214131
✉ Email this page to a colleague
The generic ingredient in LUBIPROSTONE is lubiprostone. There are ten drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.
Summary for 214131
| Tradename: | LUBIPROSTONE |
| Applicant: | Zydus Pharms |
| Ingredient: | lubiprostone |
| Patents: | 0 |
Pharmacology for NDA: 214131
| Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for 214131
Suppliers and Packaging for NDA: 214131
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 214131 | ANDA | Zydus Pharmaceuticals USA Inc. | 70710-1641 | 70710-1641-1 | 100 CAPSULE in 1 BOTTLE (70710-1641-1) |
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 214131 | ANDA | Zydus Pharmaceuticals USA Inc. | 70710-1641 | 70710-1641-6 | 60 CAPSULE in 1 BOTTLE (70710-1641-6) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 8MCG | ||||
| Approval Date: | Mar 23, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 24MCG | ||||
| Approval Date: | Mar 23, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
